These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 38605407

  • 1. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
    Shao YX, Liang CL, Su YY, Lin YT, Lu ZK, Lin RZ, Zhou ZZ, Zeng CH, Tao CY, Liu ZC, Zhang W, Liu L.
    Orphanet J Rare Dis; 2024 Apr 11; 19(1):155. PubMed ID: 38605407
    [Abstract] [Full Text] [Related]

  • 2. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
    Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR.
    Orphanet J Rare Dis; 2022 May 12; 17(1):195. PubMed ID: 35549996
    [Abstract] [Full Text] [Related]

  • 3. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
    Grünert SC, Derks TGJ, Mundy H, Dalton RN, Donadieu J, Hofbauer P, Jones N, Uçar SK, LaFreniere J, Contreras EL, Pendyal S, Rossi A, Schneider B, Spiegel R, Stepien KM, Wesol-Kucharska D, Veiga-da-Cunha M, Wortmann SB.
    Mol Genet Metab; 2024 Mar 12; 141(3):108144. PubMed ID: 38277989
    [Abstract] [Full Text] [Related]

  • 4. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.
    Grünert SC, Elling R, Maag B, Wortmann SB, Derks TGJ, Hannibal L, Schumann A, Rosenbaum-Fabian S, Spiekerkoetter U.
    Orphanet J Rare Dis; 2020 Aug 24; 15(1):218. PubMed ID: 32838757
    [Abstract] [Full Text] [Related]

  • 5. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
    Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M.
    Blood; 2020 Aug 27; 136(9):1033-1043. PubMed ID: 32294159
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire.
    Grünert SC, Derks TGJ, Adrian K, Al-Thihli K, Ballhausen D, Bidiuk J, Bordugo A, Boyer M, Bratkovic D, Brunner-Krainz M, Burlina A, Chakrapani A, Corpeleijn W, Cozens A, Dawson C, Dhamko H, Milosevic MD, Eiroa H, Finezilber Y, Moura de Souza CF, Garcia-Jiménez MC, Gasperini S, Haas D, Häberle J, Halligan R, Fung LH, Hörbe-Blindt A, Horka LM, Huemer M, Uçar SK, Kecman B, Kilavuz S, Kriván G, Lindner M, Lüsebrink N, Makrilakis K, Mei-Kwun Kwok A, Maier EM, Maiorana A, McCandless SE, Mitchell JJ, Mizumoto H, Mundy H, Ochoa C, Pierce K, Fraile PQ, Regier D, Rossi A, Santer R, Schuman HC, Sobieraj P, Spenger J, Spiegel R, Stepien KM, Tal G, Tanšek MZ, Torkar AD, Tchan M, Thyagu S, Schrier Vergano SA, Vucko E, Weinhold N, Zsidegh P, Wortmann SB.
    Genet Med; 2022 Aug 27; 24(8):1781-1788. PubMed ID: 35503103
    [Abstract] [Full Text] [Related]

  • 7. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report.
    Rossi A, Miele E, Fecarotta S, Veiga-da-Cunha M, Martinelli M, Mollica C, D'Armiento M, Mozzillo E, Strisciuglio P, Derks TGJ, Staiano A, Parenti G.
    Ital J Pediatr; 2021 Jul 02; 47(1):149. PubMed ID: 34215305
    [Abstract] [Full Text] [Related]

  • 8. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b.
    Grünert SC, Gautschi M, Baker J, Boyer M, Burlina A, Casswall T, Corpeleijn W, Çıki K, Cotter M, Crushell E, Derks TGJ, Haas D, Kilavuz S, Kingma SDK, Korman SH, Kozek A, de Laet C, Mundy H, Nassogne MC, Quintero V, Rossi A, Spenger J, Spiegel R, Stephenne X, Stojkov D, Tal G, Veiga-da Cunha M, Wortmann SB.
    Mol Genet Metab; 2024 Jun 02; 142(2):108486. PubMed ID: 38733639
    [Abstract] [Full Text] [Related]

  • 9. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial.
    Li Z, Zhang X, Chen H, Zeng H, Wu J, Wang Y, Ma N, Lan J, Zhang Y, Niu H, Shang L, Jiang X, Yang M.
    Sci Rep; 2024 Apr 15; 14(1):8630. PubMed ID: 38622211
    [Abstract] [Full Text] [Related]

  • 10. Case report: The success of empagliflozin therapy for glycogen storage disease type 1b.
    Klinc A, Groselj U, Mlinaric M, Homan M, Markelj G, Mezek Novak A, Sirca Campa A, Sikonja J, Battelino T, Zerjav Tansek M, Drole Torkar A.
    Front Endocrinol (Lausanne); 2024 Apr 15; 15():1365700. PubMed ID: 38919482
    [Abstract] [Full Text] [Related]

  • 11. Impact of genotype on neutropenia in a large cohort of Serbian patients with glycogen storage disease type Ib.
    Sarajlija A, Djordjevic M, Kecman B, Skakic A, Pavlovic S, Pasic S, Stojiljkovic M.
    Eur J Med Genet; 2020 Mar 15; 63(3):103767. PubMed ID: 31536830
    [Abstract] [Full Text] [Related]

  • 12. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib.
    Grünert SC, Rosenbaum-Fabian S, Schumann A, Selbitz AC, Merz W, Gieselmann A, Spiekerkoetter U.
    JIMD Rep; 2022 Jul 15; 63(4):303-308. PubMed ID: 35822091
    [Abstract] [Full Text] [Related]

  • 13. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
    Maiorana A, Tagliaferri F, Dionisi-Vici C.
    Front Endocrinol (Lausanne); 2023 Jul 15; 14():1145111. PubMed ID: 37152929
    [Abstract] [Full Text] [Related]

  • 14. Clinical analysis and long-term treatment monitoring of 3 patients with glycogen storage disease type Ib.
    Du C, Li Z, Wei H, Zhang M, Hu M, Zhang C, Luo X, Liang Y.
    BMC Med Genomics; 2021 Mar 17; 14(1):81. PubMed ID: 33731098
    [Abstract] [Full Text] [Related]

  • 15. A novel SLC37A4 missense mutation in GSD-Ib without hepatomegaly causes enhanced leukocytes endoplasmic reticulum stress and apoptosis.
    Xu Q, Tang H, Duan L, Zuo X, Shi X, Li Y, Zhao H, Zhang H.
    Mol Genet Genomic Med; 2021 Jan 17; 9(1):e1568. PubMed ID: 33280276
    [Abstract] [Full Text] [Related]

  • 16. [Investigation on the treatment of empagliflozin in glycogen storage disease type Ⅰb].
    Jiang JJ, Ma MS, Wei M, Qiu ZQ.
    Zhonghua Er Ke Za Zhi; 2024 Jun 02; 62(6):526-529. PubMed ID: 38763873
    [Abstract] [Full Text] [Related]

  • 17. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
    Chou JY, Jun HS, Mansfield BC.
    J Inherit Metab Dis; 2015 May 02; 38(3):511-9. PubMed ID: 25288127
    [Abstract] [Full Text] [Related]

  • 18. Genetic characterization of GSD I in Serbian population revealed unexpectedly high incidence of GSD Ib and 3 novel SLC37A4 variants.
    Skakic A, Djordjevic M, Sarajlija A, Klaassen K, Tosic N, Kecman B, Ugrin M, Spasovski V, Pavlovic S, Stojiljkovic M.
    Clin Genet; 2018 Feb 02; 93(2):350-355. PubMed ID: 28685844
    [Abstract] [Full Text] [Related]

  • 19. Impact of hematopoietic stem cell transplantation in glycogen storage disease type Ib: A single-subject research design using 13C-glucose breath test.
    Turki A, Stockler S, Sirrs S, Duddy K, Ho G, Elango R.
    Mol Genet Metab Rep; 2023 Mar 02; 34():100955. PubMed ID: 36632325
    [Abstract] [Full Text] [Related]

  • 20. Molecular biology and gene therapy for glycogen storage disease type Ib.
    Chou JY, Cho JH, Kim GY, Mansfield BC.
    J Inherit Metab Dis; 2018 Nov 02; 41(6):1007-1014. PubMed ID: 29663270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.